Purpose: To examine the efficacy of valaciclovir (VACV) oral formulation as an alternative to topical treatments in a case of herpetic keratitis.
A cyclovir (ACV), 1,2 valaciclovir (VACV), 3 trifluorothymidine, [4] [5] [6] famciclovir, [7] [8] [9] [10] [11] [12] [13] [14] and penciclovir 13, 14 are common medical treatments against herpes simplex virus type 1 (HSV-1). In Japan, 3% ACV eye ointment (ACV-O), 15 idoxuridine (IDU) 15 eye drops, and IDU eye ointment (IDU-O) are often prescribed to patients with herpetic keratitis. However, IDU eye drops are not as efficacious as ACV-O and can sometimes produce toxic effects on corneal epithelium. As for eye ointment, the inconvenience of multiple application (5 times daily for ACV-O) and the frequent occurrence of blurred vision after application cause problems. Therefore, new drugs for herpetic keratitis are desirable in Japan.
VACV hydrochloride (Valtrex
3 is a prodrug of ACV. VACV shows an oral bioavailability that is 5 times greater than ACV, concentration dependent, and saturable. 16 Oral VACV 500 mg twice daily has been used against HSV eruption along with ACV 200 mg 5 times/d for treating herpetic keratitis. Here, we report the efficacy of oral VACV in a case of herpetic keratitis and describe the results of our experiments with orally administered VACV in a mouse model of this disease.
CASE REPORT
The patient was a 61-year-old man who had experienced recurrent corneal erosions starting in February 2000. On June 25, 2002, he visited Kinki University Hospital, where a pseudodendritic lesion was observed in his left eye. On presentation, his corrected left visual acuity was 1.0 3 Sph + 0.75 D = Cyl 21.5 DA 3 75°. Ten-day treatment with 3% ACV-O was started on July 25, and the lesion was healed 1 week later. Meanwhile, HSV DNA in the eye wash sample was below the limit of detection by real-time polymerase chain reaction (PCR) using a previously reported method. 17 Because the patient had undergone right eye extraction in 1967 because of thermal burn, continuous application of eye ointment to his left eye became too burdensome because of blurred vision to the remaining eye and he did not follow the ACV-O therapy. He visited our clinic again on February 17, 2004 , because of worsening vision and eye pain. His corrected left visual acuity was 0.5 3 Sph + 0.25 = Cyl 3 2.25DA 3 70°, and a lesion indicative of dendritic keratitis was noted (Fig. 1) . The quantity of HSV DNA was 1.0 3 10 3 copies/sample. After recognizing his difficulty in using eye ointment, we prescribed oral VACV 500 mg tablets twice daily for 7 days. Levofloxacin eye drops were also administered. On February 24, 7 days after initiation of oral VACV, the lesion was healed. Corrected left visual acuity was also improved to 1.0 3 Cyl = 21.75DA 3 70°, and HSV DNA fell to below detectable levels. Therefore, outstanding effectiveness of oral VACV against herpetic keratitis was seen in this case.
After this successful case, we occasionally prescribed oral VACV to patients with herpetic keratitis, especially in those having difficulty in continuously using ACV-O or who had deteriorated corneal epithelium caused by the adverse effects of ACV-O. 
EFFECT OF ORAL VACV ON MURINE HERPETIC KERATITIS Method
The results of this experiment have already been reported, 18 and here we present a brief review of the study. The effect of each treatment was evaluated by slit-lamp score and viral titer. Mice corneas were subjected to slit-lamp examination on PI days 3, 4, 5, and 7. The following scoring criteria were used for clinical evaluation of epithelial keratitis in mouse corneas: normal cornea, score 0; superficial punctate keratitis, score 0.5; dendritic lesion covering no more than 25% of cornea, score 1: dendritic lesion covering more than 25% of cornea, score 1.5; geographic keratitis, score 2. Mice eyes and trigeminal ganglia were taken on PI days 3, 4, 5, and 7 and homogenized in PBS by mortar and pestle. After centrifugation, the supernatant was titered on green monkey kidney (GMK) cells. Figure 2 shows the results of slit-lamp examinations for all treatment groups. On PI days 5, 6, 7, 10, 12, and 14, all 5 ACV and VACV treatment groups were significantly more effective in improving symptoms of herpetic epithelial keratitis versus PBS control (P , 0.05). Moreover, VACV 100 mg/kg was superior to VACV 50 mg/kg, ACV 50 mg/kg, and 3% ACV eye drops and equivalent to 3% ACV-O. VACV 50 mg/kg was as effective as ACV 50 mg and 3% eye drops. Figure 3 shows viral titer levels of eyeball tissue samples. Viral titers of all 5 active treatment groups were significantly lower than that of the PBS group (P , 0.05). Among all groups, that in the VACV 100 mg/kg was the lowest. Figure 4 shows viral titer levels in trigeminal ganglia tissue samples. Levels in all 5 active treatment groups were significantly lower than that of PBS (P , 0.05). Furthermore, viral titer in eyeball tissue samples in the VACV 100 mg/kg group was lower than that in the other study groups.
RESULTS

DISCUSSION
In the reported case, our decision to switch the treatment modality from ACV-O to oral VACV produced good results.
The results of the slit-lamp examination in our mouse model indicated that oral VACV is significantly more effective against herpetic epithelial keratitis compared with PBS. Of all the groups, the VACV 100mg/kg and ACV-O groups especially elicited the most favorable results (Fig. 2) . Schwab 1 proved that oral ACV is efficacious against herpetic keratitis. Bodsworth et al 19 and Weller et al 20 reported that, in human cases, the concentration levels of ACV in the blood were 25.2 and 7.1 mmol/L after oral VACVof 3000 mg/d and ACV of 4000 mg/d were administered, respectively. Our experiments also showed that VACV was more effective than ACV if it was prescribed at the same dose (Figs. 3 and 4) . Despite all these positive results, unfortunately VACV is currently not approved to treat herpetic keratitis under Japanese medical insurance coverage. Unlike in the United States, where trifluorothymidine 4-6 eye drops can be prescribed for patients with HSV-1 keratitis, ACV-O, IDU eye drops, and IDU-O are the only available treatment modalities in Japan. Among them, ACV-O is preferred because it inhibits HSV DNA by binding to DNA polymerase. However, this drug could have an adverse effect on the corneal epithelium, which sometimes results in superficial punctate keratitis. In addition, frequent application, blurred vision, and foreign body sensation after application have made it difficult for patients to follow the treatment, as in the case of the patient described above. For these reasons, we consider oral VACV as the better option for patients with herpetic keratitis.
To treat human HSV-1 keratitis, we prescribed VACV 500 mg, twice daily, which was the same dosage prescribed for patients with herpetic eruption. This dosage of VACV (1000 mg/d) was based on a calculation of 10 mg/kg, twice daily, for a person weighing 50 kg. Although the concentration level of VACV in our mouse model (50 mg/kg twice daily; 100 mg/kg twice daily) was determined according to previous studies, 7, 8 in our opinion, this level might be slightly too high for a mouse. Therefore, more experiments at lower concentrations of this drug are needed.
In conclusion, oral VACV is an effective treatment of both human and murine herpetic keratitis.
